Sodium aurothiomalate Property

storage temp. 

4°C, away from moisture

form 

Solid

color 

Off-white to light yellow

Water Solubility 

Very soluble in water. Practically insoluble in alcohol, ether

Merck 

14,4518

Safety

Hazard Codes 

Xn

Risk Statements 

20/21/22-43

Safety Statements 

36

WGK Germany 

3

RTECS 

MD5435000

Hazardous Substances Data

12244-57-4(Hazardous Substances Data)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H317May cause an allergic skin reaction

H332Harmful if inhaled

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P321Specific treatment (see … on this label).

Sodium aurothiomalate Chemical Properties,Usage,Production

Physical properties

White to yellowish white powder; odorless; metallic taste; highly soluble in water; practically insoluble in ethanol and ether.

Uses

Medicine (antirheumatic).

Uses

Sodium aurothiomalate(I) is useful for high mobility group box chromosomal protein 1 western blotting.

Definition

White to yellowish-white powder; odorless; metallic taste. Affected by light. Very soluble in water; practically insoluble in alcohol and ether; aqueous solutions are colorless to pale yellow; pH (5% solution) 5.8–6.5.

Production Methods

Gold(I) thiomalate is prepared by reacting sodium thiomalate with gold(I) halide. It is stored in the dark and otherwise protected from light.

brand name

Myochrysine (Merck), Aurolate (Pasadena, USA), Myocrisin (Rh?one-Poulenc Rorer, Denmark, Sweden, Finland), Tauredon (BYK Gulden, Germany).

Pharmaceutical Applications

Sodium aurothiomalate is a commonly used gold-based DMARD and is indicated for active progressive RA. It is administered by deep intramuscular injection. Administration is started with a test dose of 10mg followed by weekly intervals of 50 mg doses. An improvement is expected to be seen once 300–500 mg is administered. Treatment should be discontinued if there is no improvement after administering 1 g or 2months. Intervals of administration should be gradually increased to 4weeks in patients in whom an effect can be seen. If any blood disorders or other side effects such as GI bleedings or proteinuria are observed, sodium aurothiomalate should be discontinued.

Clinical Use

Active progressive rheumatoid arthritis in adults

Safety Profile

Poison by subcutaneous and intramuscular routes. Moderately toxic bj intravenous ' route. Human systemic effects: aggression, agranulocytosis, aplastic anemia, cell count changes, changes in circulation, cholestatic jaunhce, dermatitis, encephalitis, fasciculations, flaccid paralysis without anesthesia, hemorrhage, hepatitis (hepatocellular necrosis), increased body temperature, interstitial fibrosis, muscle weakness, proteinuria, recording from peripheral motor nerve, depressed renal function tests, somnolence, structural changes in nerve sheath, thrombocytopenia, uncharacterized allergc reaction, changes in blood, teeth, and supporting structures. Experimental teratogenic and reproductive effects. When heated to decomposition it emits very toxic Na2O and SOx.

Synthesis

Synthesis: a solution of thiomalic acid and 3 equivalents of sodium hydroxide are mixed with an aqueous suspension of gold(I) iodide. The product, a mixture of the mono- and disodium salts, is precipitated by the addition of ethanol.

Drug interactions

Potentially hazardous interactions with other drugs
ACE-inhibitors: flushing and hypotension reported in combination.
Penicillamine: increased risk of toxicity - avoid.

Metabolism

Mainly excreted in the urine with smaller amounts in the faeces.